Kodiak Sciences Inc
KOD$1.48B
Small CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaPALO ALTO123 employees
Drugs in Pipeline
5
Phase 3 Programs
5
Upcoming Catalysts
3
Next Catalyst
Aug 15, 2026
18wMarket Overview
Stock performance and key metrics
KOD News
Catalyst Timeline
3 upcoming, 0 past
Drug Pipeline
KSI-101
Macular Edema Secondary to Inflammation
KSI-301
Macular Edema
Tarcocimab
Diabetic Retinopathy
Tarcocimab tedromer
Wet Age-related Macular Degeneration
Aflibercept
Wet Age-related Macular Degeneration
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
KSI-101 | Phase 3 | Macular Edema Secondary to Inflammation | - | - |
KSI-301 | Phase 3 | Macular Edema | - | - |
Tarcocimab | Phase 3 | Diabetic Retinopathy | - | - |
Tarcocimab tedromer | Phase 3 | Wet Age-related Macular Degeneration | - | - |
Aflibercept | Phase 3 | Wet Age-related Macular Degeneration | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply